Artigo · Revista · 2023

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference

Olanrewaju Ayodeji Durojaye, Nkwachukwu Oziamara Okoro, Arome Solomon Odiba, Bennett Chima Nwanguma

Scientific Reports

• Acesso aberto · Dourado
• 10% mais citados do mundo
• Internacional · 2 países

Lê-lo10.1038/s41598-023-33024-2